Peptron, Inc. (087010.KQ)
KRW 98300.0
(-1.99%)
KRW 98300.0
(-1.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -15.92 Billion KRW | -5.7% |
| 2022 | -15.06 Billion KRW | -0.14% |
| 2021 | -15.04 Billion KRW | 18.17% |
| 2020 | -18.38 Billion KRW | -3.75% |
| 2019 | -17.71 Billion KRW | -375.52% |
| 2018 | -3.72 Billion KRW | 15.83% |
| 2017 | -4.42 Billion KRW | -38.73% |
| 2016 | -3.19 Billion KRW | -16.87% |
| 2015 | -2.73 Billion KRW | 10.37% |
| 2014 | -3.04 Billion KRW | -47.92% |
| 2013 | -2.05 Billion KRW | 19.54% |
| 2012 | -2.55 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.18 Billion KRW | -103.17% |
| 2024 Q1 | -4.03 Billion KRW | -23.57% |
| 2023 Q4 | -3.26 Billion KRW | 21.22% |
| 2023 Q1 | -4.01 Billion KRW | 36.5% |
| 2023 Q3 | -4.14 Billion KRW | 8.16% |
| 2023 Q2 | -4.5 Billion KRW | -12.38% |
| 2023 FY | -15.92 Billion KRW | -5.7% |
| 2022 Q4 | -6.31 Billion KRW | -107.56% |
| 2022 Q3 | -3.04 Billion KRW | 17.12% |
| 2022 Q2 | -3.67 Billion KRW | -80.97% |
| 2022 Q1 | -2.02 Billion KRW | 49.14% |
| 2022 FY | -15.06 Billion KRW | -0.14% |
| 2021 Q3 | -4.27 Billion KRW | -170.0% |
| 2021 Q1 | -5.18 Billion KRW | -6.37% |
| 2021 FY | -15.04 Billion KRW | 18.17% |
| 2021 Q2 | -1.58 Billion KRW | 69.44% |
| 2021 Q4 | -3.98 Billion KRW | 6.78% |
| 2020 Q1 | -3.66 Billion KRW | 63.21% |
| 2020 FY | -18.38 Billion KRW | -3.75% |
| 2020 Q4 | -4.87 Billion KRW | -13.05% |
| 2020 Q3 | -4.31 Billion KRW | 22.01% |
| 2020 Q2 | -5.53 Billion KRW | -51.06% |
| 2019 Q3 | -3.67 Billion KRW | -90.45% |
| 2019 Q2 | -1.93 Billion KRW | 10.45% |
| 2019 FY | -17.71 Billion KRW | -375.52% |
| 2019 Q1 | -2.15 Billion KRW | -229.39% |
| 2019 Q4 | -9.95 Billion KRW | -170.52% |
| 2018 Q1 | -1.56 Billion KRW | -38.84% |
| 2018 Q3 | -2.49 Billion KRW | -351.73% |
| 2018 FY | -3.72 Billion KRW | 15.83% |
| 2018 Q4 | -654.81 Million KRW | 73.73% |
| 2018 Q2 | 990.01 Million KRW | 163.1% |
| 2017 Q3 | -866.05 Million KRW | 27.52% |
| 2017 Q2 | -1.19 Billion KRW | 3.31% |
| 2017 Q1 | -1.23 Billion KRW | -42.45% |
| 2017 FY | -4.42 Billion KRW | -38.73% |
| 2017 Q4 | -1.12 Billion KRW | -30.48% |
| 2016 Q3 | -744.37 Million KRW | 2.01% |
| 2016 Q1 | -819.35 Million KRW | -8.27% |
| 2016 FY | -3.19 Billion KRW | -16.87% |
| 2016 Q2 | -759.66 Million KRW | 7.28% |
| 2016 Q4 | -867.58 Million KRW | -16.55% |
| 2015 Q3 | -729.6 Million KRW | 2.86% |
| 2015 FY | -2.73 Billion KRW | 10.37% |
| 2015 Q4 | -756.77 Million KRW | -3.72% |
| 2015 Q2 | -751.06 Million KRW | -51.38% |
| 2015 Q1 | -496.13 Million KRW | 0.0% |
| 2014 FY | -3.04 Billion KRW | -47.92% |
| 2014 Q2 | -765.34 Million KRW | 15.61% |
| 2014 Q1 | -906.91 Million KRW | 0.0% |
| 2014 Q3 | -734.19 Million KRW | 4.07% |
| 2013 FY | -2.05 Billion KRW | 19.54% |
| 2012 FY | -2.55 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 91.579% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | -64.221% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 440.885% |
| Bioneer Corporation | -10.58 Billion KRW | -50.39% |
| Anterogen.Co.,Ltd. | -2.84 Billion KRW | -460.462% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 372.635% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 67.456% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 75.156% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | -88.844% |
| Medy-Tox Inc. | 9.75 Billion KRW | 263.216% |
| Amicogen, Inc. | -23.28 Billion KRW | 31.633% |
| Genexine, Inc. | -66.87 Billion KRW | 76.191% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -591.607% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 78.397% |
| ALTEOGEN Inc. | -3.37 Billion KRW | -372.212% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 120.799% |
| SillaJen, Inc. | -20.36 Billion KRW | 21.834% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 214.005% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 16.647% |
| Genomictree Inc. | -8.75 Billion KRW | -81.839% |
| MedPacto, Inc. | -35.32 Billion KRW | 54.927% |
| D&D Pharmatech | 3.93 Billion KRW | 504.745% |
| EASY BIO,Inc. | 15.54 Billion KRW | 202.433% |
| GI Innovation, Inc. | -55.49 Billion KRW | 71.309% |